We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-0.86%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$272M
AUM Growth
-$70.2M
Cap. Flow
-$30.4M
Cap. Flow %
-11.2%
Top 10 Hldgs %
40.84%
Holding
92
New
12
Increased
37
Reduced
27
Closed
16

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$8.78M
2
WAT icon
Waters Corp
WAT
+$8.33M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$6.57M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.23M
5
UTHR icon
United Therapeutics
UTHR
+$3.6M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.76M
2
ABBV icon
AbbVie
ABBV
+$7.41M
3
IDXX icon
Idexx Laboratories
IDXX
+$5.14M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$5.09M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$4.87M

Sector Composition

Rank Sector Weight
1 Healthcare 96.48%
2 Industrials 1.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LNTH icon
51
Lantheus
LNTH
$6.57B
$1.42M 0.52%
21,427
-3,868
-15% -$244K
KROS icon
52
Keros Therapeutics
KROS
$222M
$1.32M 0.49%
47,788
-24,902
-34% -$1.09M
FULC icon
53
Fulcrum Therapeutics
FULC
$284M
$1.29M 0.47%
262,689
+98,236
+60% +$960K
HBIO icon
54
Harvard Bioscience
HBIO
$27.8M
$1.27M 0.47%
35,175
-28,208
-45% -$1.27M
LFCR icon
55
Lifecore Biomedical
LFCR
$181M
$1.21M 0.45%
121,618
+6,302
+5% +$62.4K
KNSA icon
56
Kiniksa Pharmaceuticals
KNSA
$6.1B
$1.21M 0.44%
124,708
+6,461
+5% +$60.3K
BCYC
57
Bicycle Therapeutics
BCYC
$284M
$1.01M 0.37%
60,426
+3,131
+5% +$66K
TKNO icon
58
Alpha Teknova
TKNO
$397M
$1.01M 0.37%
119,997
+529
+0.4% +$5.58K
STRO icon
59
Sutro Biopharma
STRO
$353M
$961K 0.35%
18,452
-1,533
-8% -$85.6K
HCAT icon
60
Health Catalyst
HCAT
$135M
$914K 0.34%
63,104
-16,642
-21% -$284K
OPNT
61
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$907K 0.33%
75,632
+43,075
+132% +$695K
CNSY
62
Cerenome, Inc. Common Stock
CNSY
$25.5M
$828K 0.3%
4,088
+18
+0.4% +$4.5K
TELA icon
63
TELA Bio
TELA
$32.3M
$764K 0.28%
108,984
+480
+0.4% +$3.98K
ZYME icon
64
Zymeworks
ZYME
$1.77B
$667K 0.25%
125,806
+6,520
+5% +$39.4K
TVTX icon
65
Travere Therapeutics
TVTX
$5.86B
$636K 0.23%
+26,250
New +$660K
MIRM icon
66
Mirum Pharmaceuticals
MIRM
$6.04B
$623K 0.23%
32,014
+1,660
+5% +$39.2K
PHAT icon
67
Phathom Pharmaceuticals
PHAT
$742M
$583K 0.21%
69,135
+3,582
+5% +$36.8K
FMTX
68
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$542K 0.2%
78,603
-45,707
-37% -$321K
ALLK
69
DELISTED
Allakos
ALLK
$502K 0.18%
160,376
+8,310
+5% +$31.1K
LXRX icon
70
Lexicon Pharmaceuticals
LXRX
$1.05B
$465K 0.17%
+250,000
New +$477K
RCKT icon
71
Rocket Pharmaceuticals
RCKT
$374M
$367K 0.14%
26,677
+1,382
+5% +$16.5K
BLRX
72
BioLineRX
BLRX
$11.7M
$365K 0.13%
7,136
+369
+5% +$20.5K
SIEN
73
DELISTED
Sientra, Inc.
SIEN
$351K 0.13%
41,918
-11,268
-21% -$154K
EIGR
74
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$332K 0.12%
1,758
+91
+5% +$18.3K
SLN
75
Silence Therapeutics
SLN
$641M
$311K 0.11%
+26,250
New +$319K
1 2
3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Parkman Healthcare Partners held 92 positions worth $272M, down 21% from $342M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Parkman Healthcare Partners withdrew a net $30.4M in Q2 2022, closing 16 positions and reducing 27 holdings. Its most notable exit was BioCryst Pharmaceuticals, an estimated $7.76M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Elevance Health worth $8.57M.

  • Parkman Healthcare Partners's largest Q2 2022 buy was Elevance Health: 17,750 shares worth $8.57M.
  • Parkman Healthcare Partners added most to CTI BioPharma Corp. (DE) Common Stock in Q2 2022, an estimated $4.23M increase.
  • Parkman Healthcare Partners's biggest Q2 2022 reduction was Aclaris Therapeutics, cutting an estimated $5.09M.
  • Parkman Healthcare Partners fully exited BioCryst Pharmaceuticals in Q2 2022, selling an estimated $7.76M.
  • Parkman Healthcare Partners's ten largest holdings make up 41% of its $272M portfolio in Q2 2022.
  • Parkman Healthcare Partners opened 12 new positions and closed 16 in Q2 2022.
  • Parkman Healthcare Partners's portfolio value fell 21% quarter-over-quarter to $272M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2022, filed 12 Aug 2022.